Detalhes bibliográficos
| Ano de defesa: |
2008 |
| Autor(a) principal: |
SILVA, Ediane Batista da
 |
| Orientador(a): |
KIPNIS, Ana Paula Junqueira
|
| Banca de defesa: |
Não Informado pela instituição |
| Tipo de documento: |
Tese
|
| Tipo de acesso: |
Acesso aberto |
| Idioma: |
por |
| Instituição de defesa: |
Universidade Federal de Goiás
|
| Programa de Pós-Graduação: |
Doutorado em Ciência Animal
|
| Departamento: |
Ciências Agrárias
|
| País: |
BR
|
| Palavras-chave em Português: |
|
| Palavras-chave em Inglês: |
|
| Área do conhecimento CNPq: |
|
| Link de acesso: |
http://repositorio.bc.ufg.br/tede/handle/tde/1199
|
Resumo: |
Several aspects of the bovine tuberculosis were analyzed in this study. The immunogenicity of recombinant MPT-51 (rMPT-51), Ag-85 and M. bovis-BCG were characterized in an immunosorbent assay, where 208 serum samples from positive intradermal tuberculin test (ITT) animals and 54 serum samples from ITT negative animals where analyzed. M. bovis-BCG and Ag-85 were strongly recognized by antibodies from naturally infected cattle. Additionally, the clinical status of the animals were correlated with the ITT positivity, with the specific production of IL-4 by TCD4 and TCD8 positive lymphocytes, and with nitric oxide (NO) production by macrophages from naturally tuberculosis infected bovine peripheral blood. ITT positive animals showed TCD4+IL4+ cells specific to M. bovis-BCG extract. High background levels of TCD8+IL-4+ lymphocytes were observed in ITT positive animals independent of the stimuli. When cell cultures where stimulated with M. bovis-BCG protein extract, there was no observed difference in NO production between the groups. Naturally tuberculosis infected bovine presented TCD4+IL4+ cells specific for M. bovis- BCG and a preserved NO production. Finnally, the immunogenicity of rMPT-51 use as a proteic sub-unit vaccine was evaluated in BALB/c mice, with two different adjuvants, incomplete Freund and CpG DNA. For this, mice were immunized and challenged with M. tuberculosis. Immunization with rMPT-51 antigen and either adjuvant induced, in the lungs, a migration increase of TCD5+IFN + cells specific for rMPT-51, when compared to controls (P<0.05). rMPT-51 plus CpG DNA presented a better performance among the different vaccination schemes tested, in part due to the ability of stiulate TCD5+IFN + cells and hampering the bacterial load, thus preserving the functional integrity of challenged mice lungs |
